RVL Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2022

BRIDGEWATER, N.J., March 09, 2022 (GLOBE NEWSWIRE) — RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Barclays Global Healthcare Conference 2022, as follows: Date:Time:Webcast:Wednesday, March 16, 202211:15 a.m. EThttps://cc.webcasts.com/barc002/031522a_js/?entity=85_1GFQ11B   The webcast will be available thereafter via the Company’s website www.rvlpharma.com website under the “Investor & News” section. About RVL Pharmaceuticals plcRVL Pharmaceuticals plc (Nasdaq: RVLP) is a specialty pharmaceutical company focused on the development and commercialization of products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc., is the Company’s ophthalmic and medical aesthetics subsidiary supporting UPNEEQ®. Investor and Media Relations for RVL Pharmaceuticals plcLisa M. WilsonIn-Site Communications, Inc.T: 212-452-2793E: [email protected]